transmembrane and coiled-coil domain family 1Genealiases: []
Q-omics provides the consensus-scored TMCC1 profile across patient tissues and cancer cell-line models. TMCC1 expression is associated with patient survival in 29 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, TMCC1 is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, TMCC1 RNA expression shows 21,126 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight MESO, KIRC, and ACC as cancer lineages where TMCC1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TMCC1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TMCC1 survival associations across molecular data types. TMCC1 RNA expression shows survival associations in the most cancer types (29), followed by mutation status (6) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TMCC1 RNA expression–survival associations across cancer types. High TMCC1 expression shows unfavorable associations in MESO, PAAD, LIHC, ACC and LUSC, but favorable associations in KIRC. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify MESO as the clearest survival context for TMCC1 RNA expression.
This table summarizes TMCC1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for TMCC1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TMCC1 shows higher tumor expression in KIRC, HNSC, KIRP, LIHC, BLCA and BRCA. The KIRC box plot shows higher TMCC1 RNA expression in tumor versus normal tissue (log2 FC = +2.212, t-test p < 0.001).
This table shows molecular features associated with TMCC1 in patient tissues and cancer cell lines. In patient samples, TMCC1 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, TMCC1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BLOOD_Leukemia.
